Publications

The material below is provided to support scientific exchange. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Treatment with vutrisiran in people with transthyretin amyloidosis with cardiomyopathy: A plain language summary

Publication Details

Future Cardiology

May 2025

Access Here

Author(s)

Marianna Fontana¹, Julian D Gillmore¹, Ronald M Witteles², Ben Laryea³, Marc Dworkin⁴, Ann Payne⁵, Fran Kochman⁶, Satish Eraly⁶, Mathew S Maurer⁷

Affiliations

¹National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, London, UK; ²Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA; ³Patient author, London, UK; ⁴Patient author, Morris Plains, NJ, USA; ⁵Amyloidosis Research Consortium, Newton, MA, USA; ⁶Alnylam Pharmaceuticals, Cambridge, MA, USA; ⁷Columbia University Irving Medical Center, New York, NY, USA

PMID

40371908

DOI

10.1080/14796678.2025.2493019

Publication Materials

Visit website/URL/link

Treatment with vutrisiran in people with transthyretin amyloidosis with cardiomyopathy: A plain language summary

Presentation

Manuscript

Publications

Treatment with vutrisiran in people with transthyretin amyloidosis with cardiomyopathy: A plain language summary

Publication Details

Author(s)

Affiliations

PMID

DOI

Publication Materials

Visit website/URL/link

Related Materials

Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis

Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation

Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study

Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy

Effect of patisiran on stroke volume in hereditary transthyretin-mediated amyloidosis: insights from pressure–volume analysis of the APOLLO study

Warning !

Confirmation !

Update Password